363 related articles for article (PubMed ID: 25356728)
1. Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.
Mostaghel EA; Morgan A; Zhang X; Marck BT; Xia J; Hunter-Merrill R; Gulati R; Plymate S; Vessella RL; Corey E; Higano CS; Matsumoto AM; Montgomery RB; Nelson PS
PLoS One; 2014; 9(10):e111545. PubMed ID: 25356728
[TBL] [Abstract][Full Text] [Related]
2. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
Mostaghel EA; Marck BT; Plymate SR; Vessella RL; Balk S; Matsumoto AM; Nelson PS; Montgomery RB
Clin Cancer Res; 2011 Sep; 17(18):5913-25. PubMed ID: 21807635
[TBL] [Abstract][Full Text] [Related]
3. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
4. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.
Yu Z; Chen S; Sowalsky AG; Voznesensky OS; Mostaghel EA; Nelson PS; Cai C; Balk SP
Clin Cancer Res; 2014 Mar; 20(6):1590-600. PubMed ID: 24449822
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.
Cao B; Qi Y; Zhang G; Xu D; Zhan Y; Alvarez X; Guo Z; Fu X; Plymate SR; Sartor O; Zhang H; Dong Y
Oncotarget; 2014 Mar; 5(6):1646-56. PubMed ID: 24722067
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
[TBL] [Abstract][Full Text] [Related]
8. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
Watson PA; Chen YF; Balbas MD; Wongvipat J; Socci ND; Viale A; Kim K; Sawyers CL
Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16759-65. PubMed ID: 20823238
[TBL] [Abstract][Full Text] [Related]
9. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
Zhu Y; Dalrymple SL; Coleman I; Zheng SL; Xu J; Hooper JE; Antonarakis ES; De Marzo AM; Meeker AK; Nelson PS; Isaacs WB; Denmeade SR; Luo J; Brennen WN; Isaacs JT
Oncogene; 2020 Nov; 39(45):6935-6949. PubMed ID: 32989253
[TBL] [Abstract][Full Text] [Related]
10. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
[TBL] [Abstract][Full Text] [Related]
11. Antiandrogenic mechanisms of pesticides in human LNCaP prostate and H295R adrenocortical carcinoma cells.
Robitaille CN; Rivest P; Sanderson JT
Toxicol Sci; 2015 Jan; 143(1):126-35. PubMed ID: 25324206
[TBL] [Abstract][Full Text] [Related]
12. Inverse Regulation of DHT Synthesis Enzymes 5α-Reductase Types 1 and 2 by the Androgen Receptor in Prostate Cancer.
Audet-Walsh É; Yee T; Tam IS; Giguère V
Endocrinology; 2017 Apr; 158(4):1015-1021. PubMed ID: 28324044
[TBL] [Abstract][Full Text] [Related]
13. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.
Yamashita S; Lai KP; Chuang KL; Xu D; Miyamoto H; Tochigi T; Pang ST; Li L; Arai Y; Kung HJ; Yeh S; Chang C
Neoplasia; 2012 Jan; 14(1):74-83. PubMed ID: 22355276
[TBL] [Abstract][Full Text] [Related]
14. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
[TBL] [Abstract][Full Text] [Related]
15. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.
Sun S; Sprenger CC; Vessella RL; Haugk K; Soriano K; Mostaghel EA; Page ST; Coleman IM; Nguyen HM; Sun H; Nelson PS; Plymate SR
J Clin Invest; 2010 Aug; 120(8):2715-30. PubMed ID: 20644256
[TBL] [Abstract][Full Text] [Related]
16. Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.
Pham S; Deb S; Ming DS; Adomat H; Hosseini-Beheshti E; Zoubeidi A; Gleave M; Guns ES
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():436-44. PubMed ID: 25201454
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
18. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
[TBL] [Abstract][Full Text] [Related]
19. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.
Li Z; Bishop AC; Alyamani M; Garcia JA; Dreicer R; Bunch D; Liu J; Upadhyay SK; Auchus RJ; Sharifi N
Nature; 2015 Jul; 523(7560):347-51. PubMed ID: 26030522
[TBL] [Abstract][Full Text] [Related]
20. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
